GLP-1 Drugs and Your Gallbladder: The Relative Risk and the Absolute One

Both of these are true, and you need both. In relative terms the risk roughly doubles: a meta-analysis of 76 randomized trials covering 103,371 people found gallbladder and biliary disease at 2.29 times the placebo rate in trials run for weight loss.^[1] In absolute terms it stays small: the Wegovy label reports gallstones in 1.6% of patients against 0.7% on placebo.^[3] A doubling of a small number is still a small number, and it is still a doubling. Below is what drives it, and the symptoms that mean you should be seen today rather than at your next appointment.

What the label reports

Acute gallbladder disease has its own warning section in the Wegovy prescribing information, and unlike most of what circulates about it, the label gives absolute numbers from its own trials.^[3]

That bottom row deserves its own sentence. The rate in adolescents was more than double the adult rate, and the label says so directly: gallbladder events were more common in treated patients aged 12 and over than in treated adults.^[3] Anyone weighing this drug for a teenager is weighing a different risk profile than the adult trials describe.

What the pooled trials say

The largest analysis of this question gathered 76 randomized trials covering 103,371 patients and found the composite of gallbladder or biliary disease raised by 37% overall — a relative risk of 1.37, with a confidence interval from 1.23 to 1.52 that does not cross 1.^[1] Broken out, gallstones came in at 1.27, inflammation at 1.36, and biliary disease at 1.55.

Then it did the thing that matters here, and split the trials by what they were for.

Three gradients, all pointing the same way, and each of the three splits reached statistical significance in its own right.^[1] Higher dose, longer use, and treating weight rather than blood sugar all carry more of this risk. Weight-loss dosing is the highest of the licensed dose ranges, which is a large part of why that first row sits where it does — and it is the row describing most people reading this.

Is it just the weight loss?

This is the sensible objection, and it has a real basis: losing weight quickly is itself a known cause of gallstones, so a drug that causes rapid weight loss would produce more of them without doing anything to the gallbladder directly. If that were the whole story, the risk would not be a property of the drug at all.

The label addresses it. After acknowledging that substantial or rapid weight loss raises gallstone risk on its own, it states that acute gallbladder disease was still more common on Wegovy than on placebo after the degree of weight loss was accounted for.^[3]

The excess did not disappear when the weight loss was taken out of it. Some of this belongs to the drug.

That does not make it large. It makes it real, which is a different claim, and it is the one the evidence actually supports.

Tirzepatide, and the pancreatitis question

A separate meta-analysis looked only at tirzepatide, pooling 9 trials and 9,871 participants against placebo, basal insulin and other GLP-1 drugs. The composite of gallbladder or biliary disease came in at a relative risk of 1.97.^[2] The individual components — gallstones alone, inflammation alone — did not reach significance on their own, which is what tends to happen when a real effect is split across categories that are each too small to show it.

The same analysis looked at pancreatitis, which is the complication people ask about most and fear most. It found a relative risk of 1.46 with a confidence interval running from 0.59 to 3.61.^[2] That interval includes 1, which means the data are consistent with no increase at all. The authors concluded tirzepatide appears safe on this measure, and were careful to say that is a statement about the evidence available rather than a guarantee.

Pancreatitis remains a Section 5 warning on every one of these labels regardless, and the reason is that a rare event needs a very large dataset to rule out. Absence of a signal in 9,871 people is reassuring. It is not the same as absence of risk.

What to do with this

Not stop the drug on your own. The risk described here is small in absolute terms and it sits against a set of benefits measured in the same trials, which our semaglutide timeline and tirzepatide timeline set out. A history of gallstones, a previous gallbladder removal, or a planned rapid loss are all things worth raising with your prescriber before starting rather than after.

The dose and duration gradients are for that conversation too, not for self-management. Our side-effect timeline shows when each drug's reported effects tend to appear, and the constipation guide covers the gastrointestinal effects that are common rather than rare.